Russia Announces Success of Cancer Vaccine

Alexander Gintsburg, Scientific Director of the Gamaleya National Research Center for Epidemiology and Microbiology, reported on Tuesday (May 5, 2026) that only a slight rise in temperature was recorded after administering the cancer vaccine.

According to him, the first patient to receive the cancer vaccine did not suffer from any serious adverse reactions after being given the vaccine, with only one slight increase in body temperature recorded.

Gintsburg explained that the patient who received the vaccine suffers from stage three cancer.

It is worth noting that on April 1 of last month, the first patient in Russia received the personalized cancer vaccine, designated for the treatment of melanoma skin cancer, "Neoncovac," which was produced by the National Research Radiological Medical Center affiliated with the Russian Ministry of Health, and developed in cooperation with the Gamaleya National Center and the Blokhin National Medical Research Center of Oncology.

This drug is used to treat adult patients with inoperable or metastatic melanoma skin cancer.